Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

An FDA Advisory Committee Voted in Favor of Approving Akcea Therapeutics’ Product, WAYLIVRA, for FCS Syndrome.

May 14, 2018 0

Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA), an affiliate of Ionis Pharmaceuticals, announced that the Advisory Committee of the U.S. …

Cures for Hemophilia A and B? See Also: Why EXEL Was a Loser Yesterday

May 11, 2018 0

SPARK THERAPEUTICS, SANGAMO THERAPEUTICS AND SALK INSTITUTE CURING HEMOPHILIA? Hemophilia is an inherited bleeding disorder …

An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio

May 7, 2018 0

The Week in Review #22 What Went Right or Wrong in the Biotech Sector During the …

The FDA Approves Portola Pharmaceuticals’ Andexxa®. The First and ONLY Antidote for the Reversal of Factor Xa Inhibitors

May 4, 2018 0

The U.S. Food and Drug Administration (FDA) has approved Portola’s (PTLA) drug Andexxa®, the first and only antidote indicated for …

A Gratifying Exelixis Quarterly Results

May 3, 2018 0

It is obvious that Exelixis’ (EXEL) first quarter results do not justify the selling of EXEL during the whole quarter, …

Inspiring News from a Small Firm

May 2, 2018 0

Following the news announcing that Amgen’s (AMGN) drug KYPROLIS® (carfilzomib) extended the lives of patients with relapsed or refractory …

Amgen Has More Good News. What Is Going on with the CRISPR Gene Editing Firms?

May 1, 2018 0

A couple of days following the news that the Committee for Medicinal Products for Human Use (CHMP) …

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

April 30, 2018 0

The Week in Review #21 Part 2 THE MARKET (2) - Our remarks in the past Week …

ImmunoGen Stock Flied on Ovarian Cancer Drug News

April 27, 2018 0

The Independent Data Monitoring Committee (IDMC) decided that ImmunoGen (IMGN) Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent …

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

April 26, 2018 0

NEKTAR Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY) are collaborating to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential …

Alnylam’s RNAi Product Patisiran Has More Positive News

April 25, 2018 0

The Market The Stock Market is Still under pressure, which is frightening common investors, pressuring them …

The Biotech Revolution is Alive and Speeding

April 24, 2018 0

The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

April 12, 2018 0

Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in …

Illumina’s Contribution to Practicing Precision Medicine

April 11, 2018 0

When we reiterated that Illumina (ILMN) is the engine of the biotechnology evolution we meant it. We have …

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

April 10, 2018 0

NOVARTIS TO ACQUIRE AVEXIS A few months ago, Novartis (NVS) CEO agreed to cash out of the company’s …

Let’s Go Shopping

April 6, 2018 0

In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did not …

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

April 5, 2018 0

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If They Sell the Best of the Best Biotechnology Firms …

Why Investors Caused a Selloff of Alnylam’s Stock

April 2, 2018 0

Alnylam (ALN) is probably experiencing a stock selloff following the announcement of successful results from Pfizer’s (PFE) drug tafamidis. …

News from PTC Therapeutics, Celgene and Heron Therapeutics

March 29, 2018 0

IN THE NEWS PTC THERAPEUTICS PTC Therapeutics (PTCT) stock, which dipped yesterday, probably on news announcing a …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

An FDA Advisory Committee Voted in Favor of Approving Akcea Therapeutics’ Product, WAYLIVRA, for FCS Syndrome.

Cures for Hemophilia A and B? See Also: Why EXEL Was a Loser Yesterday

An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio

The FDA Approves Portola Pharmaceuticals’ Andexxa®. The First and ONLY Antidote for the Reversal of Factor Xa Inhibitors

A Gratifying Exelixis Quarterly Results

Inspiring News from a Small Firm

Amgen Has More Good News. What Is Going on with the CRISPR Gene Editing Firms?

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

ImmunoGen Stock Flied on Ovarian Cancer Drug News

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

Alnylam’s RNAi Product Patisiran Has More Positive News

The Biotech Revolution is Alive and Speeding

Real Breakthroughs

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Illumina’s Contribution to Practicing Precision Medicine

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

Let’s Go Shopping

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

Why Investors Caused a Selloff of Alnylam’s Stock

News from PTC Therapeutics, Celgene and Heron Therapeutics